Business Wire

NY-CITI-PRIVATE-BANK

7.9.2022 15:11:40 CEST | Business Wire | Press release

Share
Citi Private Bank and Cambridge Family Enterprise Group Offer a Roadmap for Family Enterprises to Navigate Through the Turbulent 2020s

Citi Private Bank today released The Future of Family Enterprise: Turbulence and Transformation in the 2020s, a report that’s the result of a year-long study in collaboration with the research and education division of Cambridge Family Enterprise Group (CFEG). Two-thirds of families surveyed for the report say they are moderately to extremely concerned about turbulence ahead, including how it will impact the next generation of leaders. This report examines those major concerns and provides the latest thinking, strategies and approaches going forward.

It’s clear that most businesses and industries will be disrupted or at least seriously impacted by the turbulence of the 2020s. In today’s complex and hyper-connected world, the pace of change has accelerated, disruptions occur more frequently, and a crisis anywhere can have a butterfly effect with global ramifications. Family-owned businesses and family offices will be affected, and those that aren’t prepared to address new threats and opportunities will be left behind. Family-run organizations—and the families that own them—require a distinct set of strategies to ensure their continued strength and resilience.

“At Citi Private Bank, we’re committed to helping global families continue their success into future generations. This study identifies a unique blueprint especially for enterprising families to prosper through today’s highs and lows,” says Ida Liu, Global Head of Citi Private Bank. “From having difficult conversations around transfer in leadership to investing in new technology, this report can be used to spark important multigenerational conversations within families about how to proactively adapt to upcoming challenges as well as opportunities.”

The Future of Family Enterprise study and interview research shows that enterprising families expect turbulent times ahead and recognize the imperative to change – although, they are less certain about their ability to change in the ways that are needed to succeed. While generally optimistic about their future success, they are more confident about their ability to perform well through the 2020s (10 years) than through the next generation (25 years).

The report aims to help families design effective short-term and long-term strategies to meet the challenges on the horizon by explaining how family enterprises can change course and set strategies to be on an effective path. It describes how the global macro-landscape has shifted, key dimensions of the new family enterprise success formula, and presents five strategies for implementing it:

  1. Reorient and retool your owners: Ensuring owners are well-equipped for today’s fast-changing, hyperconnected world is increasingly important for family enterprise success.

  2. Get ready to pivot: The ability to pivot to address threats and seize opportunities is the most defining characteristic of successful families.

  3. Accelerate your digital transformation: Strong digital capabilities often translate to strong financial performance and family enterprises must catch up.

  4. Make social impact a priority: Holistically approaching social impact, whether through community activities, philanthropy or sustainable investing, will be key for families in the coming decade.

  5. Engage and revitalize your family: Success requires a commitment to develop family governance and a family culture that includes all generations and types of talent.

“In today’s ever-changing world, the very way families think about stewardship needs to change,” says Dr. John Davis, MIT Professor and CFEG chairman, who led the study. “Instead of focusing on just preserving and passing the traditional family business, good stewardship today must be understood as growing multiple kinds of value according to the family’s values. This might include preserving the family’s traditional business, or not. Each generation can, and often needs to, grow value with different assets and activities, which requires families today to deploy an agile strategy for what they own.”

The report can be downloaded here.

About Citi Private Bank and CFEG:

Citi Private Bank is dedicated to serving worldly and wealthy individuals and families, providing customized private banking across borders. With around $500 billion in total client business, the franchise serves clients across 50 cities in over 100 countries. Citi Private Bank helps clients grow and preserve wealth, finance assets, make cash work harder, safeguard assets, preserve legacies, and serve family and family business needs. The firm offers clients products and services covering capital markets, managed investments, portfolio management, trust and estate planning, investment finance, banking and aircraft finance, art advisory and finance, and sports finance.

Cambridge Family Enterprise Group (CFEG) is a globally recognized authority on family enterprise and family wealth. Founded by Professor John Davis in 1989, CFEG is a thought leadership, advisory, education and research organization dedicated to helping owning families worldwide achieve multigenerational success and navigate changing times. Cambridge Institute for Family Enterprise (CIFE) is its research and education division. Additional information can be found at cfeg.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906006060/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye